舒丽启能治疗肠易激综合征的多中心临床研究

A Muticenter Clinical Trial of Cerekinon Treat on IBS

本研究采用多中心开放临床试验 ,治疗 76例IBS患者。通过治疗前后各项临床症状的分级评分及化验检查 ,以验证舒丽启能治疗IBS的有效性和安全性。结果显示 ,总有效率为 70 .2 4%。对各项症状缓解率为 :腹痛 97.1% ,腹胀 86 .4% ,恶心呕吐 6 6 .7% ,大便频率异常 94.4% ,稀便 95 .3% ,粘液便 94.1% ,里急后重 86 .1% ,排便困难 83.3% ,排便不尽感 85 .1%。本组病人在治疗过程中 ,均无明显的不良反应。结果表明 ,舒丽启能是一种治疗IBS安全有效的新药。

A muticenter open trial was carried out in 76 patients with Irritable bowel syndrome (IBS) to assess the efficacy and safety of cerekinon in controlling the symptoms of IBS and evaluate improvement of the symptom before and after administration. The result showed that the total efficacy was 70.24%. The improvement rate of each symptom: abdominal pain 2.1%, abdominal distension 86.4%, nause and vomiting 66.7%, tenesmus 86.1%, dyschezia 83.3%, mucus stool 94.1%, watery stool 95.3%, abnormal frequency of bowel action 94.4%, constipation 85.1%. The patients in this study showed no siginificant adverse reaction. The study was to determine the safety and efficacy on IBS of Cerekinon.